- Home
- LRMR vs DBL Comparison
LRMR vs DBL Comparison
Compare LRMR & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LRMR | DBL |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.0M | 295.3M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | LRMR | DBL |
|---|---|---|
| Price | $2.97 | $15.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 63.0K |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.67% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $14.49 |
| 52 Week High | $5.37 | $16.01 |
Technical Indicators
Market Signals| Indicator | LRMR | DBL |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 39.28 |
| Support Level | $2.89 | $15.00 |
| Resistance Level | $3.12 | $15.18 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 13.89 | 1.17 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.